Results 181 to 190 of about 308,520 (290)

Decision Rules in Frequentist and Bayesian Hypothesis Testing: P-Value and Bayes Factor. [PDF]

Int J Public Health
Fordellone M, Schiattarella P, Nicolao G, Signoriello S, Chiodini P.   +4 more
europepmc   +1 more source

Self-matched learning to construct treatment decision rules from electronic health records. [PDF]

Stat Med, 2022
Xu T, Chen Y, Zeng D, Wang Y.
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

FEDERATED LEARNING OF ROBUST INDIVIDUALIZED DECISION RULES WITH APPLICATION TO HETEROGENEOUS MULTIHOSPITAL SEPSIS POPULATION. [PDF]

Ann Appl Stat
Chen X, Talisa VB, Tan X, Qi Z, Kennedy JN, Chang CH, Seymour CW, Tang L.   +7 more
europepmc   +1 more source

Correction to: "Optimal Individualized Decision Rules Using Instrumental Variable Methods". [PDF]

J Am Stat Assoc, 2021
Qiu H, Carone M, Sadikova E, Petukhova M, Kessler RC, Luedtke A.   +5 more
europepmc   +1 more source

DECISIONS AND RULINGS [PDF]

The Bulletin of the National Tax Association, 1918
openaire   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials. [PDF]

Pharm Stat, 2022
Meyer EL, Mesenbrink P, Dunger-Baldauf C, Glimm E, Li Y, König F, EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) Consortium.   +6 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Clinical Decision Rules: A Starting Place in Medical Education, Not a Destination. [PDF]

J Grad Med Educ
Woods WA, Barnes BH, Waggoner-Fountain LA.   +2 more
europepmc   +1 more source